Antiretroviral therapies in HIV-1 infection

Bibliography

• FISCHL MA, RICHMAN DD, GRIECO MH eta].: The efficacy of azidothymidine (AZT) in the treatment of partici-pants with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. New Engl. J. Med. (1987) 317:185–191.
   Google Scholar
• VOLBERDING PA, LACAKOS SW, KOCH MA et al.: Zi-dovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. New Engl. J. Med. (1990) 322 (14) :941–949.
   Google Scholar
• COOPER DA, GATELL JM, KROON S et al.: Zidovudine in persons with asymptomatic HIV infection and CD4 cell counts greater than 400 per cubic millimeter. New Engl. J. Med. (1993) 329(5) :297–303.
   PubMed Web of Science ®Google Scholar
• VOLBERDING PA, LAGAKOS SW, CRIMES JM et al: A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell count of 500 or more per cubic millimeter. New Engl. J. Med. (1995) 333:401–407.
   PubMed Web of Science ®Google Scholar
• CONCORDE COORDINATING COMMITTEE: MRC/ANRSrandomised double-blind controlled trial in immediate and deferred zidovudine in symptom-free HIV infec-tion. Lancet (1994) 343:871–881.
   PubMed Web of Science ®Google Scholar
• DELTA COORDINATING COMMITTEE: DELTA: a random-ised double-blind controlled trial comparing combina-tions of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet (1996) 348:283–291.
   PubMed Web of Science ®Google Scholar
• HAMMER SM, KATZENSTEIN DA, HUGHES MD eta].: Atrial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. New Engl. J. Med. (1996) 335:1081–1090.
   Google Scholar
• SARAVOLATZ LD, WINSLOW DL, COLLINS G et al: Zi-dovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. New Engl. J. Med. (1996) 335:1099–1106.
   PubMed Web of Science ®Google Scholar
• O'BRIEN WA, HARTIGAN PM, MARTIN D et al.: Changes inplasma 11IV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. New Engl. J. Med. (1996) 334:426–431.
   Google Scholar
• MFLLORS JW, RINALDO Jr., CR, GUPTA P et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 272:1167–1170.
   Google Scholar
• KATZENSTEIN DA, HAMMER SM, HUGHES MD eta].: The relation of virologic and immunologic markers to clini-cal outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. New Engl. J. Med. (1996) 335:1091–1098.
   Google Scholar
• BARTLETT JG: Protease inhibitors for HIV infection.Ann. Intern. Med. (1996) 124:1086–1087.
   PubMed Web of Science ®Google Scholar
• KITCHEN VS, SKINNER C, ARIYOSHI K et al: Safety andactivity of saquinavir in HIV infection. Lancet (1995) 345:952–955.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ M, SAAG M, POWDERLY WG et al: A pre-liminary study of ritonavir, an inhibitor of 11IV-1 pro-tease, to treat 11IV-1 infection. New Engl. J. Med. (1995) 333:1534–1539.
   PubMed Web of Science ®Google Scholar
• DANNER SA, CARR A, LEONARD JM et al: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of 11IV-1 protease. New Engl. J. Med. (1995) 333:1528–1533.
   PubMed Web of Science ®Google Scholar
• ERON JJ, BENOIT SL, JEMSEK J et al.: Treatment with lamivudine, zidovudine, or both in 'IN-positive pa-tients with 200 to 500 CD4+ cells per cubic millimeter. New Engl. J. Med. (1995) 333:1662–1669.
   PubMed Web of Science ®Google Scholar
• PLUDA JM, COOLEY TP, MONTANER JS et al: A Phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in pa-tients with advanced human immunodeficiency virus infection. J. Infect. Dis. (1995) 171:1438–1447.
   PubMed Web of Science ®Google Scholar
• CAESAR COORDINATING COMMITTEE: Randomised trialof addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with 11IV-1 infection: the CAESAR trial. Lancet (1997) 349:1413–1421.
   PubMed Web of Science ®Google Scholar
• FREIMUTH WW, WATHEN LK, COX SR et al: Delavirdine(DLV) in combination with zidovudine (ZDV) causes sustained antiviral and immunological effects in 11IV-1 infected individuals. 3rd Conference on Retroviruses and Opportunistic Infections. Washington Oanuary 1996). Ab-stract LB8a.
   Google Scholar
• FREIMUTH WW, CHUANG-STEIN CJ, GREENWALD CA et al:Delavirdine (DLV)+ didanosine (ddI) combination ther-apy has sustained surrogate marker response in ad-vanced 11IV-1 population. 3rd Conference on Retrovir uses and Opportunistic Infections. Washington Oanuary 1996). Abstract LB8b.
   Google Scholar
• VELLA S, LAZZARIN A, CAROSI G et al.: A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Antiviral. Ther. (1996) 1:129–140.
   PubMedGoogle Scholar
• SALCO MP, BEATTIE D, BRAGMAN K et al.: Saquinavir (Invirase, SQV) vs. livid (Zalcitabine, ddC) vs. combi-nation as treatment for advanced HIV infection in patients discontinuing/unable to take Retrovir (Zi-dovudine, ZDV)., ar International Conference on AIDS. Vancouver (July 1996). Abstract Mo.B.410.
   Google Scholar
• LALEZARI J, HAUBRICH R, BURGER HU et al: Improved survival and decreased progression of HIV in patients treated with Saquinavir (Invirase, SQV) plus livid (zal-citabine, ddC). XI International Conference on AIDS. Van-couver (July 1996). Abstract LB.B.6033.
   Google Scholar
• MASSARI F, STASZEWSKI S, BERRY P etal.: A double-blind, randomized trial of Indinavir (MK-639) alone or with zidovudine vs. zidovudine alone in zidovudine naive patients. 35th Inteiscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco (September 1995). Abstract LB–6.
   Google Scholar
• BERRY P, KAHN J, COOPER R et al. Antiretroviral activity and safety of Indinavir (IDV) alone and in combination with Zidovudine (ZDV) in ZDV-naive patients with CD4 counts of 50–500 cells/mm3. XI International Conference on AIDS. Vancouver (July 1996). Abstract Th.B.6019.
   Google Scholar
• CATHE J, BURKHARDT B, HAWLEY P eta].: A randomized Phase II study of Viracept, a novel HIV protease inhibi-tor, used in combination with stavudine vs. stavudine alone. XI International Conference on AIDS.Vancouver (July 1996). Abstract Mo.B.413.
   Google Scholar
• COLLIER AC, COOMBS RW, SCHOENFELD DA et al: Treat-ment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. NewEngl. J. Med. (1996) 334:1011–1017.
   PubMed Web of Science ®Google Scholar
• D'AQUILA RT, HUGHES MD, JOHNSON VA et at Nevirap-ine, zidovudine, and didanosine compared with zi-dovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-con-trolled trial. Ann. Intern. Med. (1996) 124:1019–1030.
   PubMed Web of Science ®Google Scholar
• MASSARI F, CONANT M, MELLORS J et al.: A Phase II open-label, randomized study of the triple combination of indinavir, zidovudine (WV) and didanosine (ddl) versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients. 3rd Conference on Retroviruses and Opportunistic Infections. Washington (Janu-ary 1996). Abstract 200.
   Google Scholar
• CULICK RM, MELLORS J, HAVLIR D et al.: Potent and sustained antiretroviral activity of indinavir in combi-nation with zidovudine and lamivudine. 3rd Conference on Retroviruses and Opportunistic Infections. Washington (January 1996). Abstract LB7.
   Google Scholar
• GULICK RM, MELLORS J, HAVLIR D et al: Potent and sustained antiretroviral activity of indinavir OD')), zi-dovudine (ZDV) and lamivudine (3TC). XI International Conference on AIDS. Vancouver (July 1996). Abstract Th.B.931.
   Google Scholar
• CAMERON DW, HEATH-CHIOZZI M, KRAVCIK S et al.: Prolongation of life and prevention of AIDS complica-tions in advanced HIV immunodeficiency with rito-navir: update. XI International Conference on AIDS. Vancouver (July 1996). Abstract Mo.B.411.
   Google Scholar
• CAMERON DW, HEATH-CHIOZZI M, KRAVCIK S et al: Prolongation of life and prevention of AIDS complica-tions in advanced HIV immunodeficiency with rito-navir. 3rd Conference on Retroviruses and Opportunistic Infections. Washington (January 1996). Abstract LB6a.
   Google Scholar
• NABULSI A, REVICKI D, CONWAY D et al.: Quality of life consequences of adding ritonavir to current antiviral therapy for advanced HIV patients. XI International Conference on AIDS. Vancouver (July 1996). Abstract LB .B.6046.
   Google Scholar
• BOULTON A: HIV trial stopped early after good results. Br. Med. J. (1997) 314:699.
   PubMed Web of Science ®Google Scholar
• Second Crixivan study stopped early. Scrip (1997) 2218:13.
   Google Scholar
• LANGE JMA: Current problems and the future of an-tiretroviral drug trials. Science (1997) 276:548–550.
   PubMed Web of Science ®Google Scholar
• CARPENTER CCLJ, FISCHL MA, HAMMER SM et al: An-tiretroviral therapy for HIV infection in 1996. Recom-mendations of an international panel. JAMA (1996) 276:146–154
   Google Scholar
• BHIVA GUIDELINES CO-ORDINATING COMMITTEE Brit- ish HIV Association guidelines for antiretroviral treat- ment of HIV seropositive individuals. Lancet (1997) 349:1086–1092.
   PubMed Web of Science ®Google Scholar
• COFFIN JM: IIW population dynamics in vivo: implica-tions for genetic variation, pathogenesis, and therapy. Science (1995) 267:483–489.
   PubMed Web of Science ®Google Scholar
• PERELSON AS, NEUMANN AU, MARKOWITZ MHIV-1dynamics in viva virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 271:1582–1586.
   PubMed Web of Science ®Google Scholar
• SALMINEN MO, ROBERTSON D, SHARP PM eta].: Continu-ous in vivo recombination between 11W-1 strains of genetic subtypes A and C. XI International Conference on AIDS. Vancouver Ouly 1996). Abstract Tu.A.511.
   Google Scholar
• HEATH-CHIOZZI M, LEONARD J, HENRY D eta].: Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced IIW immu-nodeficiency. 3rd Conference on Retroviruses and Oppor-tunistic Infections. Washington (January 1996). Abstract LB6b.
   Google Scholar
• MOYLE GJ: Use of viral resistance patterns to antiretrovi-ral drugs in optimising selection of drug combinations and sequences. Drugs (1996) 52:168–185.
   PubMed Web of Science ®Google Scholar
• TAMALET C, LAFEUILLADE A, FANTINI J, POGGI C, YAHI N: Quantification of 11W-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy. AIDS (1997) 11:895–901.
   PubMed Web of Science ®Google Scholar
• CHUN T-W, CARRUTH L, FINZI D et al.: Quantification of latent tissue reservoirs and total body viral load in 11IV-1 infection. Nature (1997) 387:183–188.
   PubMed Web of Science ®Google Scholar
• PERELSON AS, ESSUNCER P, CAO Y et al.: Decay charac-teristics of HIV-1-infected compartments during combi-nation therapy. Nature (1997) 387:188–191.
   PubMed Web of Science ®Google Scholar
• MICHIE CA, MCLEAN A, ALCOCK C, BEVERLEY PC: Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature (1992) 360:264–265.
   PubMed Web of Science ®Google Scholar
• SCHOOLEY RT: THE 141W94 INTERNATIONAL STUDY GROUP: preliminary data from a Phase IIII study on the safety and antiviral efficacy of 141W94 plus 1592U59 in HIV-infected patients with 150 to 400 CD4+ cells/mm3. 4th Conference on Retroviruses and Opportunistic Infections. Washington (January 1997). Abstract LB3.
   Google Scholar
• SHAM H, KEMPF D, MOLLA A et al: Design, synthesis andbiological properties of ABT-378, a highly potent IIW protease inhibitor. 4th Conference on Retroviruses and Opportunistic Infections. Washington (January 1997). Ab-stract 14.
   Google Scholar
• RICHMAN D, HAVLIR D, CORBEIL J et al: Nevirapineresistance mutations of human immunodeficiency vi-rus Type 1 selected during therapy. J. Vim]. (1994) 68:1660–1666.
   Web of Science ®Google Scholar
• RUIZ N AND THE DUPONT MERCK STUDY GROUP: A double-blind pilot study to evaluate the antiretroviral activity, tolerability of DMP 266 in combination with indinavir. 4th Conference on Retroviruses and Opportunistic Infections. Washington (January 1997). Abstract LB2.
   Google Scholar
• SCHAPIRO JM, WINTERS MA, STEWART F et al: The effectof high dose saquinavir on viral load and CD4+ T-cell counts in 11W-infected patients. Ann. Intern. Med. (1996) 124:1039–1050.
   PubMed Web of Science ®Google Scholar
• KRAVCIK S, SAHAI K, KERR B et al.: Nelfinavir mesylate increases saquinavir-soft gel capsule exposure in HIV+ patients. 4th Conference on Retroldruses and Opportunistic Infections. Washington (January 1997). Abstract 371.
   Google Scholar